Year-over-year, this metric declined by 100.0%, from $8.00M to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful commercialization of intellectual property through partners, while a decrease may indicate expiring patents or reduced partner activity.
This metric represents the total gross revenue recognized from licensing intellectual property and royalty agreements wi...
Common in biotech and pharmaceutical firms that out-license non-core assets or partner on early-stage clinical programs.
mrna_segment_licensing_and_royalty_revenue_total_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $30.00M | $7.00M | $5.00M | $8.00M | $2.00M | $2.00M | $0.00 | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | -76.7% | -28.6% | +60.0% | -75.0% | +0.0% | -100.0% | — |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | -93.3% | -71.4% | -100.0% | -100.0% |